- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Melan A (MLANA), also known as MART-1, is a melanocyte-specific protein involved in melanosome formation and pigment production and is widely recognized as a definitive marker of melanocyte lineage. Its expression is tightly restricted to melanocytes and melanocyte-derived cells, where it contributes to the structural organization and function of melanosomes. Because MLANA expression reflects lineage identity rather than general cellular activity, it is extensively used to identify melanocytic cells in both normal tissues and disease states. MLANA Antibody reagents are therefore critical tools for distinguishing melanocyte-derived populations from surrounding non-melanocytic cells.
MLANA antibody, also referred to as Melan A antibody or MART-1 antibody in the literature, recognizes a cytoplasmic protein with highly restricted expression in melanocytic cells. The MLANA Antibody clone rMLANA/9404 is particularly suited for studies focused on melanocyte lineage identification, where detection of MLANA expression enables clear separation of melanocytic cells from epithelial, mesenchymal, and lymphoid populations. In normal tissues, MLANA expression is confined to melanocytes located within the basal layer of the epidermis and related pigment-producing structures, while most other tissues remain negative, providing a high level of specificity for lineage determination.
From a developmental perspective, MLANA expression is closely linked to melanocyte differentiation and maturation. As neural crest-derived precursor cells commit to the melanocytic lineage, MLANA expression increases alongside other melanocyte-specific proteins involved in pigment synthesis and organelle formation. This makes MLANA a valuable marker for studying lineage commitment, cellular differentiation, and pigment cell development in both in vivo systems and experimental models. Detection of MLANA supports identification of mature melanocytes and evaluation of differentiation status in melanocyte biology research.
In cancer research, MLANA expression is strongly associated with melanoma and other melanocytic tumors, where cytoplasmic staining highlights tumor cells derived from melanocyte lineage. Its lineage specificity allows for clear identification of melanocytic tumors even in complex or poorly differentiated tumor environments. Unlike broader tumor-associated markers, MLANA provides direct insight into cellular origin, supporting accurate classification and interpretation of tumor phenotype in research settings.
The restricted expression profile of MLANA also minimizes background staining in non-melanocytic tissues, enabling clear visualization of melanocyte-derived cells in heterogeneous samples. This enhances interpretability and supports reliable identification of melanocytic populations across diverse experimental contexts.
Clone rMLANA/9404 enables consistent and reproducible detection of Melan A in applications requiring precise identification of melanocyte lineage. Its performance supports detailed analysis of melanocytic differentiation, cellular identity, and pigment cell biology, making it well suited for studies of melanoma, melanocyte development, and lineage-specific expression.
This antibody is part of the Melan-A antibody collection, where additional MLANA/MART-1 antibodies for various applications can be explored.
Optimal dilution of the MLANA Antibody / Melanocyte Lineage Marker Antibody should be determined by the researcher.
Recombinant full-length human MART-1/Melan-A protein was used as the immunogen for the recombinant MLANA antibody.
Aliquot the recombinant MLANA antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
MLANA antibody, Melan A antibody, MART-1 antibody, melanocyte marker antibody, melanoma lineage antibody, melanocytic differentiation antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.